Facon, T. Et Al. 2021. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21 .

Facon, T., Moreau, P., Martin, T. G., Spicka, I., Oriol, A., Koh, Y., ... Lim, A.(2021). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21.

Facon, Thierry Et Al. "Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021

Facon, Thierry Et Al. "Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021

Facon, T. Et Al. (2021) . "Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21.

@article{article, author={Thierry Facon Et Al. }, title={Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2021}